Resources with keywords: MVA-BN



WHO grants approval for use of Bavarian Nordic’s mpox vaccine in adolescents
World Health Organization (WHO)
16 October 2024

A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox

Mpox vaccine is safe and generates a robust antibody response in adolescents
NIH
16 October 2024

MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic.

Go to Top